B型肝炎の種特異性制限に関する新知見と新モデル構築への可能性(New clues to hepatitis B species restriction could help build a novel model for studying infection and testing therapies)

ad

2026-04-22 ロックフェラー大学

ロックフェラー大学の研究チームは、B型肝炎の治療法開発を加速する新たなマウスモデルを開発した。B型肝炎ウイルス(HBV)はヒト特異的で従来モデルでは再現が難しかったが、本モデルではヒトに近い感染環境を再現し、ウイルスの増殖や免疫応答を詳細に解析可能となった。これにより、抗ウイルス薬や免疫療法の効果検証がより精密に行えるようになる。慢性B型肝炎は依然として世界的な健康課題であり、本成果は根治療法の開発やワクチン改良に向けた重要な基盤を提供する。今後の創薬研究や臨床応用への貢献が期待される。

B型肝炎の種特異性制限に関する新知見と新モデル構築への可能性(New clues to hepatitis B species restriction could help build a novel model for studying infection and testing therapies)
Transmission electron microscopic image showing hepatitis B virus virions in orange (Credit: CDC/Dr. Erskine Palmer)

<関連情報>

マウス肝細胞におけるB型肝炎ウイルスの共有結合閉環状DNA形成は、後期侵入阻害機構を明らかにする Hepatitis B virus covalently closed circular DNA formation in murine hepatic cells uncovers a late entry block

Xupeng Hong, Georgia Brousseau, Hsuan-An Chen, +7 , and Charles M. Rice
Proceedings of the National Academy Sciences  Published:April 21, 2026
DOI:https://doi.org/10.1073/pnas.2603476123

Significance

Hepatitis B virus (HBV) chronically infects nearly 300 million people worldwide, but studies of its immunopathogenesis and therapeutics have been limited by the lack of an HBV-susceptible immunocompetent mouse model. A long-standing belief is that murine hepatocytes cannot form covalently closed circular DNA (cccDNA), the viral episome required for persistence. Here, we developed a piggyBac-based system to efficiently generate stable, inducible HBV-replicating cell lines and showed that murine hepatocytes can form cccDNA through the intracellular amplification pathway. Our results reveal that, beyond human HBV receptor expression, the dominant restriction occurs at a late entry step before nucleocapsid uncoating. Defining this remaining barrier will provide critical insights into HBV host tropism and help guide the development of fully HBV-permissive mouse models.

Abstract

Chronic hepatitis B virus (HBV) infection affects nearly 300 million people worldwide. Progress in understanding HBV immunopathogenesis and developing curative therapies has been hindered by the lack of suitable small animal models. HBV exhibits strict host and tissue tropism, with productive infection largely restricted to human and chimpanzee hepatocytes. Murine hepatocytes are resistant to HBV infection, even with ectopic expression of the human HBV entry receptor sodium taurocholate cotransporting polypeptide (huNTCP), because they apparently fail to form covalently closed circular DNA (cccDNA), the viral episome required for productive infection and persistence. To investigate the mechanisms restricting HBV infection in murine cells, we developed a piggyBac transposon-based system that efficiently generates inducible stable cell lines supporting HBV replication and cccDNA formation via intracellular amplification—a pathway that shares similar nucleocapsid uncoating and nuclear import of relaxed circular DNA (rcDNA) that occur during de novo infection. Remarkably, all tested murine hepatocyte and hepatoma cell lines, across multiple mouse genetic backgrounds, supported cccDNA formation at levels comparable to human cells, indicating that nucleocapsid uncoating and rcDNA nuclear import are not limited in mice. Given that huNTCP-expressing murine hepatocytes support hepatitis D virus infection, which shares early entry events with HBV, our findings reveal that the dominant restriction to HBV infection in huNTCP-expressing murine hepatocytes lies at a late entry step preceding nucleocapsid uncoating. By defining this mechanistic block, our study advances understanding of HBV host tropism and provides a foundation for facilitating development of fully HBV-susceptible mouse models.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました